QQQ   348.82 (-1.70%)
AAPL   177.82 (-0.78%)
MSFT   323.38 (-3.09%)
META   263.60 (-2.77%)
GOOGL   122.50 (-3.78%)
AMZN   121.23 (-4.25%)
TSLA   224.57 (+1.47%)
NVDA   374.75 (-3.05%)
NIO   7.76 (-1.52%)
BABA   85.29 (-1.63%)
AMD   117.83 (-5.15%)
T   16.09 (+2.68%)
F   13.59 (+5.11%)
MU   67.06 (-0.71%)
CGC   0.72 (-2.69%)
GE   106.08 (+0.59%)
DIS   92.53 (+0.40%)
AMC   4.73 (+1.94%)
PFE   38.89 (+1.36%)
PYPL   64.04 (-1.51%)
NFLX   399.77 (+0.12%)
QQQ   348.82 (-1.70%)
AAPL   177.82 (-0.78%)
MSFT   323.38 (-3.09%)
META   263.60 (-2.77%)
GOOGL   122.50 (-3.78%)
AMZN   121.23 (-4.25%)
TSLA   224.57 (+1.47%)
NVDA   374.75 (-3.05%)
NIO   7.76 (-1.52%)
BABA   85.29 (-1.63%)
AMD   117.83 (-5.15%)
T   16.09 (+2.68%)
F   13.59 (+5.11%)
MU   67.06 (-0.71%)
CGC   0.72 (-2.69%)
GE   106.08 (+0.59%)
DIS   92.53 (+0.40%)
AMC   4.73 (+1.94%)
PFE   38.89 (+1.36%)
PYPL   64.04 (-1.51%)
NFLX   399.77 (+0.12%)
QQQ   348.82 (-1.70%)
AAPL   177.82 (-0.78%)
MSFT   323.38 (-3.09%)
META   263.60 (-2.77%)
GOOGL   122.50 (-3.78%)
AMZN   121.23 (-4.25%)
TSLA   224.57 (+1.47%)
NVDA   374.75 (-3.05%)
NIO   7.76 (-1.52%)
BABA   85.29 (-1.63%)
AMD   117.83 (-5.15%)
T   16.09 (+2.68%)
F   13.59 (+5.11%)
MU   67.06 (-0.71%)
CGC   0.72 (-2.69%)
GE   106.08 (+0.59%)
DIS   92.53 (+0.40%)
AMC   4.73 (+1.94%)
PFE   38.89 (+1.36%)
PYPL   64.04 (-1.51%)
NFLX   399.77 (+0.12%)
QQQ   348.82 (-1.70%)
AAPL   177.82 (-0.78%)
MSFT   323.38 (-3.09%)
META   263.60 (-2.77%)
GOOGL   122.50 (-3.78%)
AMZN   121.23 (-4.25%)
TSLA   224.57 (+1.47%)
NVDA   374.75 (-3.05%)
NIO   7.76 (-1.52%)
BABA   85.29 (-1.63%)
AMD   117.83 (-5.15%)
T   16.09 (+2.68%)
F   13.59 (+5.11%)
MU   67.06 (-0.71%)
CGC   0.72 (-2.69%)
GE   106.08 (+0.59%)
DIS   92.53 (+0.40%)
AMC   4.73 (+1.94%)
PFE   38.89 (+1.36%)
PYPL   64.04 (-1.51%)
NFLX   399.77 (+0.12%)
NYSEAMERICAN:IBIO

iBio (IBIO) Stock Forecast, Price & News

$0.79
-0.03 (-3.67%)
(As of 06/7/2023 ET)
Compare
Today's Range
$0.77
$0.83
50-Day Range
N/A
52-Week Range
$0.36
$16.51
Volume
241,060 shs
Average Volume
2.15 million shs
Market Capitalization
$13.24 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

IBIO stock logo

About iBio (NYSEAMERICAN:IBIO) Stock

iBio, Inc. is a biotechnology company, which engages in the development and manufacture of biotherapeutics. It operates through the Biopharmaceuticals and Bioprocessing segments. The Biopharmaceuticals segment involves molecule discovery, development, and licensing activities. The Bioprocessing segment includes contract development and manufacturing services for recombinant proteins. The company was founded on April 17, 2008 and is headquartered in Bryan, TX.

Receive IBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for iBio and its competitors with MarketBeat's FREE daily newsletter.

IBIO Stock News Headlines

The Stock That's Brining Lithium Back To America!
The American Energy Crisis Is Very Real And This Stock Is Solving That Problem On U.S Soil
iBio: Q3 Earnings Insights
The Stock That's Brining Lithium Back To America!
The American Energy Crisis Is Very Real And This Stock Is Solving That Problem On U.S Soil
iBio Inc. stock rises Friday, outperforms market
Why Is iBio (IBIO) Stock Up 124% Today?
See More Headlines

IBIO Price History

IBIO Company Calendar

Last Earnings
11/15/2021
Today
6/07/2023
Fiscal Year End
6/30/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NYSEAMERICAN:IBIO
Previous Symbol
NASDAQ:IBIO
Employees
49
Year Founded
N/A

Profitability

Net Income
$-50,300,000.00
Pretax Margin
-11,133.67%

Debt

Sales & Book Value

Annual Sales
$2.38 million
Book Value
$7.27 per share

Miscellaneous

Free Float
16,398,000
Market Cap
$13.24 million
Optionable
Not Optionable
Beta
-3.19

Key Executives

  • Martin B. Brenner
    Chief Executive & Scientific Officer
  • Mike Jenkins
    Vice President-Operations
  • Felipe Duran
    CFO, Vice President-Financial Planning & Analysis
  • Phan Dillon
    Vice President, Head-Research & Development
  • Matthew Luter
    Vice President-Information Technology













IBIO Stock - Frequently Asked Questions

Should I buy or sell iBio stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for iBio in the last year. There are currently 2 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" IBIO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in IBIO, but not buy additional shares or sell existing shares.
View IBIO analyst ratings
or view top-rated stocks.

How were iBio's earnings last quarter?

iBio, Inc. (NYSEAMERICAN:IBIO) posted its quarterly earnings results on Monday, November, 15th. The biotechnology company reported ($1.00) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.25) by $0.25. The biotechnology company earned $0.21 million during the quarter.

When did iBio's stock split?

Shares of iBio reverse split on Tuesday, October 11th 2022. The 1-25 reverse split was announced on Tuesday, October 11th 2022. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, October 11th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

What other stocks do shareholders of iBio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other iBio investors own include Inovio Pharmaceuticals (INO), Vaxart (VXRT), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Heat Biologics (HTBX), Novavax (NVAX), Dynavax Technologies (DVAX), Co-Diagnostics (CODX), Nokia Oyj (NOK) and Moderna (MRNA).

What is iBio's stock symbol?

iBio trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "IBIO."

Who are iBio's major shareholders?

iBio's stock is owned by a variety of institutional and retail investors. Top institutional investors include Armistice Capital LLC (4.25%), BlackRock Inc. (1.12%), Bank of New York Mellon Corp (0.71%), Renaissance Technologies LLC (0.55%), State Street Corp (0.39%) and Susquehanna International Group LLP (0.00%). Insiders that own company stock include Eastern Capital Ltd, Martin Brenner and Robert Matthew Lutz.
View institutional ownership trends
.

How do I buy shares of iBio?

Shares of IBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is iBio's stock price today?

One share of IBIO stock can currently be purchased for approximately $0.79.

How much money does iBio make?

iBio (NYSEAMERICAN:IBIO) has a market capitalization of $13.24 million and generates $2.38 million in revenue each year.

How can I contact iBio?

iBio's mailing address is 600 Madison Ave Ste 1601, NEW YORK, NY 10022-1737, United States. The official website for the company is www.ibioinc.com. The biotechnology company can be reached via phone at (979) 446-0027, via email at ir@ibioinc.com, or via fax at 302-356-1173.

This page (NYSEAMERICAN:IBIO) was last updated on 6/7/2023 by MarketBeat.com Staff

My Account -